Corrigendum to: A Portfolio-Based Approach to Optimize Proof-of-Concept Clinical Trials (Journal of Biopharmaceutical Statistics, 22, 3, (596–607), 10.1080/10543406.2011.564340);A portfolio-based approach to optimize proof-of-concept clinical trials

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 3, 2012, Pages 596-607

  Mallinckrodt, Craig ^a   Molenberghs, Geert ^b   Persinger, Charles ^a   Ruberg, Stephen ^a   Sashegyi, Andreas ^a   Lindborg, Stacy ^a  

^a ELI LILLY AND COMPANY   (United States)

^b I BioStat   (Belgium)

Author keywords

Power; Proof of concept; Type I error

Indexed keywords

ARTICLE; CALCULATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONCEPT ANALYSIS; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; MOTIVATION; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROOF OF CONCEPT;

EID: 84859203764     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2016.1178564     Document Type: Erratum

References (10)

1. Chen, C., Beckman, R. A. (2009a). Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. Journal of Biopharmaceutical Statistics 19(3):424-436.
2. Chen, C., Beckman, R. A. (2009b). Optimal cost-effective go-no go decisions in late-stage oncology drug development. Statistics in Biopharmaceutical Research 1(2):159-169.
3. Gelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Kahn, A., Trivedi, M. H., Ninan, P. T., Mann, J. J., Bergeson, S., Endicott, J., Kocsis, J. H., Leon, A. C., Manji, H. K., Rosenbaum, J. F. (2008). The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. Journal of Clinical Psychiatry 69(10):1513-1528.
4. Hurko, O., Ryan, J. L. (2005). Translational research in central nervous system drug discovery. NeuroRx 2:671-682.
5. Johnson, R. A., Wichern, D. W. (1992). Applied Multivariate Statistical Analysis. 3rd ed. Englewood Cliffs, NJ: Prentice Hall.
6. Kola, I., Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3:711-715.
7. Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., Molenberghs, G. (2010). Design archetypes for Phase II clinical trials in central nervous system disorders. Drug Information Journal 44(4):421-430.
8. Munos, B. H. (2009). Lessons learned from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8:959-968.
9. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., Schacht, A. L. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 9:203-214.
10. Piantadosi, S. (2005). Clinical Trials: A Methodological Perspective. 2nd ed. New York: John Wiley & Sons.